Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
6-K
Operational Other
confidence 85%
filed 2026-07-22
EX-99.1
GoldMining Inc. announced the filing of a preliminary economic assessment (PEA) technical report for its São Jorge gold project in Brazil, disclosing key project economics including NPV5% of $532 million at base case gold price and IRR of 42.4%, along with capital requirements and production profiles. This represents a material operational and strategic milestone for the mineral exploration company advancing the resource-stage project toward pre-feasibility studies and permitting.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-07-22
Item 8.01
NRX Pharmaceuticals disclosed that its subsidiary NRXD was selected by DARPA for contract negotiation on a clinical trial (SPARC-TMS) combining D-cycloserine with robotic-enabled TMS for depression treatment. This represents a material operational and strategic milestone—selection for negotiation of a potential government research award—that would affect a reasonable investor's assessment of the company's pipeline and commercial prospects, though the filing explicitly notes this is not yet a binding award.
View raw filing on EDGAR →
8-K
Operational Other
confidence 85%
filed 2026-07-22
Item 7.01
Monopar announced initiation of a rolling New Drug Application submission for ALXN1840 to the FDA for Wilson disease treatment. This is a material regulatory and operational milestone for a clinical-stage biopharmaceutical company—the transition from clinical development to formal FDA review represents a significant advancement in the product development pathway. While not a specific named event type, this clearly falls within operational/strategic business milestones that would affect investor assessment of the company's progress and prospects.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-07-22
The filing discloses quarterly financial results for Q2 2026 under Item 2.02 (Results of Operations and Financial Condition). The press release reports net income of $23.0 million ($0.39 per diluted share) and includes detailed financial metrics, balance sheet data, and operational highlights. This is a standard earnings announcement material to investors assessing the registrant's financial performance.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-07-22
Item 2.02
This is a clear earnings release disclosing quarterly and six-month financial results for Parke Bancorp, Inc. The filing explicitly states "Parke Bancorp, Inc. issued a press release to report earnings for the three and six months ended June 30, 2026" and includes detailed financial highlights (net income of $12.2 million for Q2 2026, revenue of $39.3 million, EPS of $1.03 diluted), consolidated balance sheets, and income statements. The press release is furnished as Exhibit 99.1 and is the primary content of Item 2.02.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-22
Item 5.02
Matthew Kreps was appointed to the Board of Directors of ASTROTECH Corp on July 16, 2026, increasing the board size from six to seven directors. Kreps brings extensive background in capital markets and investor relations, and received a restricted stock grant of 2,150 shares as part of his appointment.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-07-22
Item 2.02
This is a standard earnings release disclosing quarterly and year-to-date financial results for the period ended June 30, 2026. The press release reports net income of $7.8 million ($1.33 per diluted share) for Q2 2026 and $15.3 million ($2.63 per diluted share) for the six-month period, with detailed operating results, balance sheet information, and asset quality metrics. The filing explicitly states this is being furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings releases.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-07-22
Item 2.02
Cathay General Bancorp disclosed Q2 2026 quarterly earnings results, reporting net income of $92.2 million ($1.37 diluted EPS), net interest margin expansion to 3.48%, and loan/deposit growth metrics via press release furnished under Items 2.02 and 7.01.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-22
Item 5.02
AXT appointed Jia-Bin Duh as a Class III independent director effective July 16, 2026, expanding the Board from five to six members. Duh brings 30+ years of senior executive leadership at major technology companies (Hewlett-Packard, Microsoft, Cisco) and deep expertise in Greater China markets to support the company's subsidiary Tongmei and long-term growth strategy.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-07-22
Item 2.02
Live Oak Bancshares disclosed its second quarter 2026 financial results on July 22, 2026, reporting net income attributable to common shareholders of $34.7 million, or $0.74 per diluted common share. The filing includes a complete press release (Exhibit 99.1) with detailed quarterly financial statements, income statements, and balance sheets, which is the standard format for an earnings release under Item 2.02.
View raw filing on EDGAR →
6-K
Earnings release
confidence 95%
filed 2026-07-22
EX-99.1
This is a press release announcing Q2 2026 production results for Avino Silver & Gold Mines Ltd., disclosing quarterly production figures (267,305 silver oz, 2,178 gold oz, 729,929 lbs copper) and operational metrics. The document explicitly states "AVINO ANNOUNCES Q2 2026 PRODUCTION RESULTS" and includes detailed production highlights, mill throughput data, and consolidated production results comparing Q2 2026 to Q2 2025 and YTD figures. The company notes that full financial statements will be released August 12, 2026, but this production announcement is a discrete quarterly results disclosure material to investors assessing operational performance.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 92%
filed 2026-07-22
Item 1.01
The Company settled material litigation filed by the Jeffrey L. Feinberg Personal Trust against ONAR LLC alleging breach of contract and unjust enrichment on a $1.5 million Senior Secured Promissory Note. Under the settlement agreement executed July 16, 2026, the Company is obligated to pay $1.5 million principal plus 18% annual interest through February 2030, with dismissal and mutual release of claims.
View raw filing on EDGAR →
8-K
M&A activity
confidence 98%
filed 2026-07-22
Item 2.01
Vita Coco completed its acquisition of Copra, Inc. on July 22, 2026, for an initial consideration of $175 million (80% cash, 20% stock) plus contingent earnout consideration of $45–$100 million based on 2028 performance. The transaction expands Vita Coco's market share in the super-premium coconut water segment and adds manufacturing capabilities including a factory in Thailand.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-07-22
Item 2.02
Knight-Swift issued a press release on July 22, 2026 announcing its financial results for the quarter ended June 30, 2026, disclosing GAAP net income of $43.2 million, Adjusted Net Income of $102.8 million, and EPS of $0.26 (Adjusted EPS of $0.63). The filing explicitly states this is Item 2.02 (Results of Operations and Financial Condition) with the press release attached as Exhibit 99.1, which is the standard format for quarterly earnings releases.
View raw filing on EDGAR →
8-K
M&A activity
confidence 92%
filed 2026-07-22
Item 5.01
Arastou Mahjoory and Ann Mollicone each purchased 40,000 newly authorized Series B Preferred Shares (convertible into 500 common shares each) through subscription agreements dated June 22, 2026, acquiring joint control with approximately 58% voting power and materially changing the registrant's ownership and governance structure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-22
The filing discloses the appointment of Anuj Goel as Chief Financial Officer of SharonAI Holdings Inc., effective August 24, 2026. While the press release also mentions the departure of incumbent CFO Tim Broadfoot, the principal disclosed action centers on the appointment of a named executive to a C-suite officer role. The appointment is material as it affects the company's executive leadership during a growth phase.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-07-22
The filing discloses the appointment of Alexander Asgary as Chief Strategy Officer effective July 16, 2026, along with a concurrent consulting agreement providing $250,000 annual compensation plus $250,000 in warrant awards. While the filing also mentions Chris Chumas's transition to EVP of a subsidiary, the principal disclosed action centers on Asgary's appointment to a C-suite role with material compensation terms, making this an executive appointment event.
View raw filing on EDGAR →
6-K
M&A activity
confidence 95%
filed 2026-07-22
EX-99.1#2
This exhibit discloses unaudited pro forma financial information for MKDWELL Tech Inc.'s acquisition of Landvision Inc., a Hong Kong cross-border e-commerce company. The Share Purchase Agreement dated July 17, 2026 involves a US$240 million all-stock consideration (30 million shares at US$8.00 per share), representing a material acquisition that would substantially alter the combined entity's asset base (goodwill of US$239.7 million) and operational profile. This is a classic material acquisition disclosure under Item 1.01 / 2.01 equivalent for a 6-K.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-07-22
Fast Track Group disclosed entry into a Strategic Co-Brand Partnership Agreement with Sony Music on July 20, 2026, regarding a Global Digital Content Platform. The Company retains 100% IP ownership and receives 90% of net profits from projects. This is a material strategic partnership with a major entertainment entity that would affect investor assessment of the Company's growth prospects and revenue streams, but does not fit the specific M&A categories (no acquisition, merger, or change of control) and is best classified as a material operational/strategic business partnership.
View raw filing on EDGAR →
8-K
Earnings release
confidence 92%
filed 2026-07-22
The filing discloses preliminary and unaudited monthly financial performance for April–June 2026, showing net sales growth of 46% and gross profit growth of 132%, with gross margins expanding to above 35%. The press release attached as Exhibit 99.1 is titled "Worksport Announces 132% Gross Profit Growth from April to June; June 2026 Marks Strongest Month in Company History" and presents detailed monthly financial metrics. Although labeled under Item 7.01 (Regulation FD Disclosure) rather than Item 2.02, the substance is a financial results announcement material to investor assessment of the company's operational trajectory and profitability progress.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-07-22
bioAffinity announced a strategic collaboration with Pictor, Inc. to develop and commercialize next-generation diagnostic tests for asthma and COPD. The agreement integrates bioAffinity's flow cytometry expertise with Pictor's targeted proteomic platform to create high-throughput laboratory tests. This is a material operational and strategic partnership affecting the company's product development roadmap and market positioning in a large therapeutic market ($108B+ projected by 2026), but it does not fit the specific categories of M&A activity, debt issuance, or other defined event types—it is a material business collaboration and partnership milestone.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-07-22
Item 8.01
Kairos Pharma announced entry into a strategic collaboration agreement with Bayer to evaluate ENV-105 in combination with XOFIGO for metastatic castration-resistant prostate cancer. This is a material operational/strategic partnership targeting a $570M–$1.3B addressable market, but it does not constitute a material acquisition, merger, or change of control (ma_activity), nor does it fit other specific event categories. The collaboration represents a significant clinical and commercial milestone for the company's lead candidate.
View raw filing on EDGAR →
8-K
Exec departure
confidence 85%
filed 2026-07-22
Item 5.02
The principal disclosed action is the termination of Geoffrey Hitchcock, Chief Revenue Officer, effective July 23, 2026, following a for-cause determination by the Board under his Employment Agreement. While the filing also discloses a subsequent civil complaint filed by Mr. Hitchcock (Item 8.01), the core Item 5.02 event is the executive departure itself. The for-cause termination and denial of severance benefits are material to investors assessing leadership stability and potential litigation risk.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 98%
filed 2026-07-22
EX-99.1
Empro Group received a Staff Delisting Determination from Nasdaq on July 16, 2026, notifying the Company that Nasdaq has determined to delist its securities pursuant to Listing Rule IM-5101-4, citing both discretionary authority and the Company's delay in filing Form 20-F. The delisting is triggered by an SEC trading suspension order issued October 8, 2025, due to potential market manipulation. Trading suspension is scheduled for July 27, 2026, unless the Company appeals by July 23, 2026. This is a material delisting event that directly threatens the Company's continued listing and market access.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 85%
filed 2026-07-22
NextTrip entered into a securities purchase agreement with Lind Global Fund III LP on July 21, 2026, to receive $4,000,000 in funding in exchange for a Senior Secured Convertible Promissory Note of $4,600,000 principal amount and a warrant. Item 1.01 explicitly discloses "Entry into a Material Definitive Agreement" and Item 2.03 covers "Creation of a Direct Financial Obligation." While the instrument is convertible (which could suggest dilutive_issuance), the primary event is the creation of a new debt obligation—a senior secured convertible note with defined repayment terms, security interests, and covenants. The warrant issuance is ancillary consideration. This is material as it creates a significant direct financial obligation secured by all company assets.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 92%
filed 2026-07-22
Item 3.03
MicroVision announced a 1-for-15 reverse stock split explicitly "intended to increase the per-share trading price of MicroVision's common stock to satisfy the minimum bid price requirement for continued listing on the Nasdaq Capital Market." The press release states the reverse split "supports our continued Nasdaq listing," indicating the company faced delisting risk due to non-compliance with Nasdaq's minimum bid price requirement. This is a material disclosure of a listing compliance issue and the remedial action taken.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-22
The filing discloses the appointment of Mort Aaronson as a member of the Board of Directors on July 1, 2026, to fill a vacancy. The principal disclosed action is a person taking a role (board director), supported by detailed biographical information and the execution of a Director Agreement and Indemnification Agreement with specified compensation ($75,000 annually in shares). This is a clear executive appointment event.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 85%
filed 2026-07-22
EX-99.1
Intercure Ltd. is soliciting shareholder approval for a reverse 5-to-1 share split and amendment to the Articles of Association at an Extraordinary General Meeting scheduled for August 12, 2026. The reverse split is driven by a Nasdaq non-compliance notice received on February 25, 2026 for failing to maintain a minimum $1.00 bid price, with delisting risk if the reverse split is not approved by the August 24, 2026 deadline.
View raw filing on EDGAR →
6-K
Governance Other
confidence 85%
filed 2026-07-22
EX-99.1
This is a notice of an extraordinary general meeting calling for shareholder votes on a material corporate name change from "Ming Shing Group Holdings Limited" to "PMA Graphene Technology Group Inc." and corresponding amendments to the company's memorandum and articles of association. While the document is a notice rather than a vote result, the proposed name change and governance amendments are material governance events that would affect investor assessment of the company's identity and corporate structure. This is governance-related but does not fit the specific categories of exec_appointment, exec_departure, exec_compensation, or shareholder_vote_results (which applies to results, not the notice itself).
View raw filing on EDGAR →
8-K
Delisting risk
confidence 92%
filed 2026-07-22
The filing discloses a 1-for-40 reverse stock split explicitly undertaken to "enable the Company to manage continued compliance with The Nasdaq Capital Market Listing Rule 5550(a)(2)" — the minimum bid price rule. The press release states the split is "intended to increase the closing bid price of the Common Stock above $1.00 per share" to maintain Nasdaq listing compliance. This is a direct response to delisting risk triggered by failure to meet the minimum bid price requirement.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-07-22
The filing discloses completion of a Series A Rights Offering that raised approximately $21.9 million and will result in issuance of approximately 4,384,163 shares of common stock. This is a material capital-raising event involving dilutive equity issuance to existing shareholders through a rights offering, which materially affects the registrant's capitalization and shareholder ownership percentages.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 75%
filed 2026-07-22
The filing discloses multiple unregistered equity issuances in a short timeframe: (1) 500,000 commitment fee shares to Hollywood Horizons; (2) warrants to purchase up to 6,891,798 shares initially and up to 50,000,000 shares total under the warrant purchase agreement with GL PART SPV II, LLC; and (3) 6,666,667 shares sold to Lombard Street Partners, LLC. Item 3.02 explicitly confirms reliance on Section 4(a)(2) and Regulation D exemptions. These private placements and warrant issuances are highly dilutive to existing shareholders and represent material capital-raising activity typical of small-cap issuers under financial stress.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-07-22
Item 2.02
BankUnited disclosed its quarterly financial results for Q2 2026 (quarter ended June 30, 2026) via press release filed as Exhibit 99.1 under Item 2.02. The disclosure includes net income of $71 million, diluted EPS of $0.97, and comprehensive financial metrics (NIM, ROA, ROE, deposit and loan details, credit quality, and capital ratios). This is a standard quarterly earnings release that would materially affect a reasonable investor's assessment of the company's financial performance and condition.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-07-22
Item 2.02
Kinder Morgan issued a press release on July 22, 2026 announcing preliminary financial results for the quarter ended June 30, 2026, including record second quarter net income of $867 million (up 21% YoY), Adjusted EBITDA of $2,199 million (up 12% YoY), and EPS of $0.39 (up 22% YoY). The filing explicitly states the press release is furnished as Exhibit 99.1 and discusses quarterly earnings performance, which is the hallmark of an earnings release disclosure under Item 2.02.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-07-22
Item 2.02
Origin Bancorp announced its second quarter 2026 financial results on July 22, 2026, reporting net income of $33.8 million ($1.09 diluted EPS) along with comprehensive results of operations and financial highlights.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 95%
filed 2026-07-22
Item 8.01
The board of directors declared a quarterly cash dividend of $0.25 per share of common stock, payable on August 31, 2026, representing a 67% increase from the prior quarterly dividend of $0.15 per share.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 98%
filed 2026-07-22
Item 7.01
The filing discloses Matador Resources Company's Board declaration of a quarterly cash dividend of $0.375 per share payable on September 8, 2026. This is a routine but material capital allocation decision that affects shareholder returns and reflects the company's dividend policy adopted in October 2025. The disclosure is made via Item 7.01 (Regulation FD Disclosure) with a press release attached as Exhibit 99.1.
View raw filing on EDGAR →
8-K
Governance Other
confidence 92%
filed 2026-07-22
Item 5.03
Wheeler Real Estate Investment Trust amended its charter to effect a one-for-five reverse stock split, effective July 27, 2026. The reverse split restructures the company's equity capitalization, adjusts conversion rates on convertible securities, changes the CUSIP number and trading basis, and materially affects all shareholders' holdings and the company's market presentation.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-22
Item 5.02
The Board appointed Dr. Alexander Vollert as a director effective August 1, 2026. This is a clear executive appointment to the Board of Directors. While the disclosure notes that Guidewire recognized $11.3 million and $13.4 million in revenue from AXA SA (Dr. Vollert's former employer) during the relevant periods, the principal disclosed action is the appointment of a new director with significant operational and CEO experience at a major insurance company, which is material to investors assessing board composition and governance.
View raw filing on EDGAR →
8-K
Earnings release
confidence 92%
filed 2026-07-22
Item 2.02
First Community Corporation disclosed Second Quarter 2026 financial results, including net income of $7.595 million (up 46.5% year-over-year), diluted EPS of $0.80 (up 19.4% year-over-year), along with deposit and loan growth metrics and capital ratios.
View raw filing on EDGAR →
8-K
Exec departure
confidence 75%
filed 2026-07-22
Item 5.02
J. Ted Nissen retired as Executive Vice President and Chief Banking Officer of the Company and President and CEO of the Bank, effective December 31, 2026, after 31 years with the organization. His departure triggers a leadership restructuring in which the CEO and President role will be split.
View raw filing on EDGAR →
8-K
M&A activity
confidence 98%
filed 2026-07-22
Item 1.01
Progress Software entered into an Asset Purchase Agreement to acquire substantially all assets and employees of Domo's AI and Data Platform Business for approximately $400 million, with closing expected in fiscal Q4 2026. The transaction adds ~2,400 customers and is subject to customary closing conditions including HSR approval and Domo stockholder approval.
View raw filing on EDGAR →
6-K
Other material
confidence 75%
filed 2026-07-22
EX-99.1
Trinity Biotech announced a plan to change its ADS ratio from 1:20 to 1:600 (equivalent to a 1-for-30 reverse ADS split), effective July 24, 2026. The stated purposes are to regain Nasdaq compliance with the $1.00 minimum bid price requirement and to broaden the investor base. While this is a material capital structure event affecting all ADS holders, it does not fit neatly into the standard taxonomy categories (not a dilutive issuance, not a governance vote, not a periodic report). The event is clearly material to investors as it affects trading mechanics and compliance status, but the domain is structural/capital-markets rather than operational, financial, legal, or governance in the traditional sense.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-07-22
EX-99.1
Trinity Biotech announced a strategic collaboration agreement with Latch Medical to combine CGM+ biosensor technology with intradermal drug delivery, along with a planned equity investment in Latch Medical. This is a material operational and strategic partnership that expands Trinity Biotech's product platform and market opportunity in metabolic health solutions, but does not fit the specific categories of M&A activity (no acquisition/merger), equity issuance (investment is outbound, not dilutive to Trinity), or other named event types. The collaboration and investment represent a significant strategic initiative affecting the company's future direction and competitive positioning.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-07-22
Item 2.02
Cal-Maine Foods issued a press release on July 22, 2026, announcing financial results for the fourth quarter and fiscal year ended May 30, 2026. The disclosure includes detailed financial highlights (net sales, gross profit, operating income, net income, and diluted EPS), segment results, and management commentary. This is a standard earnings release filed under Item 2.02 of Form 8-K with the press release attached as Exhibit 99.1.
View raw filing on EDGAR →
6-K
Exec Compensation
confidence 92%
filed 2026-07-22
EX-99.1
The disclosure announces approval by the Nomination, Governance and Compensation Committee of a grant of 15,933 stock options to eligible employees under the Dr. Reddy's Employees Stock Option Scheme, 2018, with an exercise price of Rs. 1,206 per share and 100% vesting over 3 years. This is a compensatory arrangement for employees and falls squarely within exec_compensation. The filing is made under SEBI Regulation 30 and includes detailed terms required by the SEBI Master Circular, indicating material disclosure of equity-based compensation.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 85%
filed 2026-07-22
EX-99.1
The exhibit discloses the appointment of Dr. Sridevi Khambhampaty as Global Head of Biologics and Senior Management Personnel, effective July 22, 2026, with induction into the Management Council. This is a senior executive appointment that would materially affect investor assessment of the company's leadership and strategic direction in its biologics division. The secondary disclosure of the auditor appointment (Deloitte Haskins & Sells, LLP) is a routine auditor change that does not override the primary event.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 75%
filed 2026-07-22
EX-99.1
The Board approved on July 22, 2026, the appointment of Dr. Sridevi Khambhampaty as Global Head of Biologics and Senior Management Personnel, with induction into the Management Council.
View raw filing on EDGAR →
6-K
Earnings release
confidence 95%
filed 2026-07-22
EX-99.2
Dr. Reddy's announced consolidated financial results for Q1FY27 (quarter ended June 30, 2026), reporting revenues of ₹80.7 billion, EBITDA of ₹10.1 billion, and profit after tax of ₹4.4 billion, with a material ₹2.4 billion provision related to semaglutide API issues reducing margins by approximately 3%.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-07-22
Item 2.02
Century Communities issued a press release on July 22, 2026, announcing its second quarter 2026 financial results, including net income of $36.1 million ($1.26 per diluted share), total revenues of $927.2 million, and operational metrics such as 2,506 home deliveries and 2,615 net new contracts. The disclosure is a standard quarterly earnings announcement with consolidated financial statements and operational data, furnished as Exhibit 99.1 under Item 2.02 of the 8-K.
View raw filing on EDGAR →